Angiotensin II (AT-II)-Receptor Antagonists are Reviewed. Research focused on blocking the renin- angiotensin system (RAS) led to the discovery of angiotensin-converting-enzyme (ACE) inhibitors ...

The potential benefit of angiotensin II-receptor antagonism is not limited to well-tolerated blood pressure control. Angiotensin II has complex effects on the heart and kidneys. Blocking the ...

In particular, they were interested in being able to steer and activate the angiotensin II type 2 receptor ... only the AT2 receptor but not the other receptor, the AT1 receptor, as this would ...

The decision puts Travere and CSL in line for a first-in-class approval in IgAN for sparsentan, an oral antagonist of both endothelin type A (ETA) and angiotensin II subtype 1 (AT1) receptors ...

The dual-action agent LCZ696 blocks the angiotensin II receptor (via a valsartan moiety) and inhibits neprilysin (via an AHU377 moiety). In a phase II trial, this drug “demonstrated superior ...

This medication is an angiotensin II receptor antagonist, prescribed for high blood pressure. This medication is an angiotensin II receptor blocker (ARB), prescribed for high blood pressure either ...

An orally active, selective antagonist of the angiotensin II type 1 (AT1) receptor and the endothelin-A receptor, sparsentan has anti-inflammatory, anti-proliferative, and anti-fibrotic effects.